Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Account Payables (2020 - 2025)

Cytek Biosciences' Change in Account Payables history spans 6 years, with the latest figure at -$1.3 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 607.36% year-over-year to -$1.3 million; the TTM value through Dec 2025 reached $448000.0, down 82.65%, while the annual FY2025 figure was $448000.0, 82.65% down from the prior year.
  • Change in Account Payables reached -$1.3 million in Q4 2025 per CTKB's latest filing, down from $588000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.8 million in Q1 2022 to a low of -$2.0 million in Q2 2023.
  • Average Change in Account Payables over 5 years is $142600.0, with a median of $281500.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: soared 2383.93% in 2022, then tumbled 607.36% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$742000.0 in 2021, then fell by 22.37% to -$908000.0 in 2022, then tumbled by 97.58% to -$1.8 million in 2023, then surged by 114.38% to $258000.0 in 2024, then crashed by 607.36% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Change in Account Payables are -$1.3 million (Q4 2025), $588000.0 (Q3 2025), and $759000.0 (Q2 2025).